BFRI Biofrontera Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1858685 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.8%
TTM net income YoY61.6%
TTM EPS YoY76.4%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-14.2%
Net margin-13.8%
FCF margin-17.2%
EBITDA margin-14.0%
Returns
ROE-988.4%
ROA-28.8%
ROIC (approx.)—
Asset turnover2.09x
Leverage & solvency
Liabilities / assets75.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.25x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.07M | $12.00M | $10.08M | $17.10M | $6.99M | $9.03M | $8.59M | $12.56M |
| R&D expense | $450,000 | $448,000 | $900,000 | $787,000 | $854,000 | $870,000 | $1.21M | $783,000 |
| SG&A expense | $12.46M | $9.63M | $10.99M | $8.52M | $10.05M | $10.53M | $8.65M | $8.20M |
| Operating income | -$6.50M | -$524,000 | -$4.32M | $4.56M | -$6.28M | -$5.08M | -$4.55M | -$1.71M |
| Interest expense | — | — | — | — | — | — | $120,000 | — |
| Pretax income | -$6.42M | -$581,000 | -$4.75M | $5.64M | -$6.64M | -$5.30M | -$4.20M | -$1.40M |
| Income tax | $4,000 | $23,000 | — | $0 | $6,000 | $21,000 | -$1,000 | -$3,000 |
| Net income | -$6.42M | -$604,000 | -$4.75M | $5.64M | -$6.65M | -$5.32M | -$4.20M | -$1.40M |
| EBITDA | -$6.50M | -$524,000 | -$4.26M | $4.62M | -$6.28M | -$5.08M | -$4.52M | -$1.17M |
| EPS (basic) | -0.42 | -0.05 | -0.41 | — | -0.62 | -0.57 | -0.47 | — |
| EPS (diluted) | -0.42 | -0.05 | -0.41 | — | -0.62 | -0.57 | -0.47 | — |
| Weighted avg. shares (diluted) | 15.28M | 12.92M | 11.68M | — | 10.78M | 9.35M | 8.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.22M | $4.66M | $6.32M | $6.39M | $3.42M | $7.24M | $1.78M | $5.91M |
| Receivables | $4.79M | $5.54M | — | $7.29M | — | — | — | — |
| Inventory | $1.73M | $1.10M | $1.23M | $1.43M | $4.33M | $4.03M | $6.53M | $6.65M |
| Current assets | $11.10M | $12.44M | $13.16M | $18.08M | $14.41M | $18.82M | $15.33M | $20.70M |
| PP&E, net | $2.11M | $2.14M | $2.17M | $2.16M | $20,000 | $37,000 | $59,000 | $80,000 |
| Intangibles | $2.53M | $2.57M | $2.61M | $2.65M | $22,000 | $26,000 | $31,000 | $35,000 |
| Total assets | $21.47M | $24.06M | $24.79M | $28.56M | $15.41M | $20.14M | $16.59M | $22.10M |
| Current liabilities | $14.24M | $10.54M | $10.92M | $11.89M | $12.55M | $19.69M | $10.96M | $12.02M |
| Total liabilities | $21.71M | $18.11M | $18.72M | $18.08M | $18.00M | $24.81M | $16.12M | $17.67M |
| Shareholders' equity | -$243,000 | $5.96M | $6.07M | $10.48M | -$2.58M | -$4.67M | $469,000 | $4.43M |
| Shares outstanding | 17.95M | 14.21M | 11.87M | 11.65M | 11.65M | 10.14M | 8.87M | 8.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.43M | -$1.66M | -$70,000 | -$2.38M | -$3.82M | -$3.04M | -$4.12M | -$1.02M |
| Capital expenditure | $9,000 | $0 | $5,000 | -$1,000 | -$1,000 | $1,000 | $3,000 | $1,000 |
| Free cash flow | -$1.44M | -$1.66M | -$75,000 | -$2.38M | -$3.82M | -$3.05M | -$4.12M | -$1.02M |
| Investing cash flow | -$9,000 | $0 | -$5,000 | $3.00M | $1,000 | -$1,000 | -$3,000 | -$1,000 |
| Financing cash flow | — | — | — | $2.35M | $0 | — | — | $4.05M |
| Depreciation & amortization | $0 | $0 | $55,000 | $62,000 | $0 | $0 | $29,000 | $538,000 |
| Stock-based compensation | $224,000 | $263,000 | $342,000 | $289,000 | $236,000 | $187,000 | $239,000 | $299,000 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.